KCM
CPRX

Kornitzer Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Kornitzer Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$883K Sell
28,091
-10,768
-28% -$318K 0.02% 459
2026
Q1 		$962K Sell
38,859
-1,312
-3% -$31.3K 0.02% 398
2025
Q4 		$938K Buy
40,171
+171
+0.4% +$3.81K 0.02% 416
2025
Q3 		$788K Buy
+40,000
New +$823K 0.02% 431

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Kornitzer Capital Management's CPRX Position: Q2 2026 in Review

Kornitzer Capital Management reduced its Catalyst Pharmaceutical (CPRX) stake by 28% in Q2 2026, selling an estimated $318K and leaving 28,091 shares worth $883K. The position accounts for 0.02% of the portfolio, ranked #459.

Kornitzer Capital Management first reported a position in CPRX in Q3 2025 and has held it in 4 quarters since. The position peaked at $962K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Kornitzer Capital Management held 28,091 shares of Catalyst Pharmaceutical worth $883K as of Q2 2026.
  • Kornitzer Capital Management sold 10,768 Catalyst Pharmaceutical shares in Q2 2026, an estimated $318K.
  • Catalyst Pharmaceutical made up 0.02% of Kornitzer Capital Management's portfolio in Q2 2026, its #459 holding.
  • Kornitzer Capital Management first reported a position in Catalyst Pharmaceutical in Q3 2025 and has held it in 4 quarters since.
  • Kornitzer Capital Management's Catalyst Pharmaceutical position peaked at $962K in Q1 2026.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Kornitzer Capital Management's 13F filing for Q2 2026, filed 31 Jul 2026.